N-[5-methyl-2-(morpholin-4-yl)benzyl]-N-methylamine | 1229952-91-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 恶嗪烷类
• 英文名称: N-[5-methyl-2-(morpholin-4-yl)benzyl]-N-methylamine
• 英文别名: N-methyl-1-(5-methyl-2-morpholin-4-ylphenyl)methanamine
• CAS: 1229952-91-3
• 化学式: C₁₃H₂₀N₂O
• 分子量: 220.315
• InChiKey: ANFSUNJZRLNRKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  24.5
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET LEURS UTILISATIONS
  申请人：NUVATION BIO INC

  公开号：WO2020210383A1

  公开（公告）日：2020-10-15

  Heterocyclic compounds as Weel inhibitors are provided. The compounds may find use as therapeutic agents for the treatment of diseases and may find particular use in oncology.

  提供了一种作为Weel抑制剂的杂环化合物。这些化合物可能用作治疗疾病的治疗剂，特别是在肿瘤学中可能具有特殊用途。
• [EN] NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS<br/>[FR] NOUVEAUX DÉRIVÉS ARYLES SUBSTITUÉS, LEUR PROCÉDÉ DE PRÉPARATION ET LEURS UTILISATIONS THÉRAPEUTIQUES EN TANT QU'AGENTS ANTI-VIH
  申请人：CELLVIR

  公开号：WO2010066847A1

  公开（公告）日：2010-06-17

  The present invention concerns novel substituted aryl derivatives, their process of preparation and their use for inhibiting virus replication and for treating viral diseases or disorders such as HIV and/or HCV infection.

  本发明涉及新型取代芳基衍生物，其制备方法以及用于抑制病毒复制和治疗病毒性疾病或障碍，如HIV和/或HCV感染的用途。
• NOVEL SUBSTITUTED ARYL DERIVATIVES, THEIR PROCESS OF PREPARATION AND THEIR THERAPEUTICAL USES AS ANTI-HIV AGENTS
  申请人：Benarous Richard

  公开号：US20120022054A1

  公开（公告）日：2012-01-26

  The present invention concerns novel substituted aryl derivatives, their process of preparation and their use for inhibiting virus replication and for treating viral diseases or disorders such as HIV and/or HCV infection.

  本发明涉及新型取代芳基衍生物、其制备过程及其用于抑制病毒复制和治疗病毒性疾病或障碍，如HIV和/或HCV感染的用途。
• 8,9-DIHYDROIMIDAZOLE[1,2-A]PYRIMIDO[5,4-E]PYRIMIDINE-5(6H)-KETONE COMPOUND
  申请人：Impact Therapeutics, Inc

  公开号：EP3543242A1

  公开（公告）日：2019-09-25

  Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R7 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

  所公开的是 8,9-二氢咪唑并[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮化合物，具体由式 I 表示： 或其药学上可接受的盐或原药，其中 A 和 R1-R7 在此定义。具有式 I 的化合物是 Wee1 激酶抑制剂。因此，本公开的化合物可用于治疗由 Wee1 活性异常引起的疾病。
• 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-ones
  申请人：IMPACT THERAPEUTICS, INC.

  公开号：US10703759B2

  公开（公告）日：2020-07-07

  Disclosed are 8,9-dihydroimidazo[1,2-a]pyrimido[5,4-e]pyrimidin-5(6H)-one compounds, specifically represented by the Formula I: or a pharmaceutically acceptable salt or prodrug thereof, wherein A and R1-R7 are defined herein. Compounds having Formula I are Wee1 kinase inhibitors. Therefore, compounds of the disclosure may be used to treat diseases caused by abnormal Wee1 activity.

  所公开的是 8,9-二氢咪唑并[1,2-a]嘧啶并[5,4-e]嘧啶-5(6H)-酮化合物，具体由式 I 表示： 或其药学上可接受的盐或原药，其中 A 和 R1-R7 在此定义。具有式 I 的化合物是 Wee1 激酶抑制剂。因此，本公开的化合物可用于治疗由 Wee1 活性异常引起的疾病。